Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 55OTHER 34NIH 6NETWORK 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 45Vincristine 37Cisplatin 31Radiotherapy 30Radiation 30Carboplatin 29Dexamethasone 28Etoposide 26Biopsy 26Doxorubicin 24daratumumab 18Prednisone 18Radiotherapy, Intensity-Modulated 17durvalumab 16Platinum 16Irinotecan 16Cytarabine 16Paclitaxel 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Methotrexate 14Leucovorin 14Docetaxel 14Observation 13Lenalidomide 13Radiotherapy, Conformal 12Fluorouracil 12Calcium Dobesilate 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × pomalidomide × 1 year × Clear all
NCT04667663 2026-04-13

CPD-DARA

Cancer Trials Ireland

Phase 1 Active not recruiting
16 enrolled
Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

European Myeloma Network B.V.

Phase 3 Active not recruiting
117 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡